Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RBP4 | P02753 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068789 | 1.00 | GAA (0.52) | GAARBP4HSD11B1TRPV1ALDH1A1 | |
| SCHEMBL7066752 | 0.82 | MEN1 (0.45) | ALDH1A1 | |
| SCHEMBL7066749 | 0.82 | MEN1 (0.45) | ALDH1A1 | |
| SCHEMBL7068386 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NPSR1 | |
| SCHEMBL7068390 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NPSR1 | |
| SCHEMBL7065713 | 0.80 | CA12 (0.48) | CA12CA2CA9 | |
| SCHEMBL7065717 | 0.80 | CA12 (0.48) | CA12CA2CA9 | |
| SCHEMBL7071239 | 0.79 | SMN1; SMN2 (0.56) | ALDH1A1HRH3 | |
| SCHEMBL7071236 | 0.79 | SMN1; SMN2 (0.56) | ALDH1A1HRH3 | |
| SCHEMBL7065398 | 0.79 | NOTUM (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | GAA 156/4885RBP4 4287/4885HSD11B1 1462/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | GAA 156/4885RBP4 4287/4885HSD11B1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.